<DOC>
	<DOCNO>NCT00332891</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety SR58611A patient Generalized Anxiety Disorder . The primary objective evaluate efficacy 350 mg 700 mg dose SR58611A compare placebo patient generalize anxiety disorder ( GAD ) . The secondary objective evaluate efficacy SR58611A disability quality life patient GAD evaluate safety SR58611A</brief_summary>
	<brief_title>An Eight-Week Study Evaluate Efficacy Safety SR58611A Patients With Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<criteria>Patients suffer generalized anxiety disorder ( GAD ) define DSMIVTR criterion confirm Mini International Neuropsychiatric Interview ( MINI ) plus GAD Module Total score 14item Hamilton Anxiety Rating Scale ( HAMA ) equal 20 . Patients diagnosis Major Depressive Disorder define DSMIVTR within 6 month study entry . Patients MontgomeryAsberg Depression Rating Scale ( MADRS ) total score 18 high screening baseline visit . Patients moderate high current risk suicide . Patients current anxiety disorder assess MINI : agoraphobia , social phobia , panic disorder , obsessivecompulsive disorder , posttraumatic stress disorder , acute stress disorder . Patients lifetime history accord MINI : bipolar disorder , psychotic disorder , antisocial personality disorder . Patients severe unstable concomitant medical condition accord Investigator 's judgment . Females pregnant lactating . Female patient childbearing potential must use effective method birth control entire study period . Patients positive test illicit drug include urine drug screen . Participation clinical trial experimental therapy within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>Anti-Anxiety Agents</keyword>
	<keyword>control Clinical Trials</keyword>
</DOC>